Category: Investment, Biotech, Pharma
Biotech Stock Breaking News: SUNSHINE BIOPHARMA (OTCBB:SBFM) INITIATES IND-ENABLING STUDIES FOR ITS ANTICANCER COMPOUND, Adva-27a
Visit this company: Sunshine Biopharma Inc.
Montreal, Quebec, Canada - November 13, 2012 (Menafn - Investorideas.com Newswire) Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has initiated the IND-Enabling studies for Adva-27a, the Company’s flagship oncology drug candidate. Adva-27a is a small molecule that has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR) in vitro. The newly synthesized material which the Company took delivery of recently has been used to initiate several IND-Enabling experiments which are currently in progress. Some of these experiments include physical characterization of the molecule as well as various biological activity assays including protein binding, enzyme inhibition, cytotoxicity, in vivo clearance and xenograft studies in mice. The results of the IND-Enabling studies constitute an integral part of an IND Application (Investigational New Drug Application) which the Company must file with the regulatory authorities in the US and Canada as part of the drug development and approval process.
"This is a major milestone in our development of Adva-27a", said Dr. Steve N. Slilaty, Sunshine Biopharma's CEO. "We are very excited to be at this point, the last step before Phase I clinical trials", he added.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
Published at the investorideas.com newswire
Sign up for the free investor news and biotech stock alerts
Research biotech stocks at the Investor Ideas Biotech stocks Directory
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure:
Investorideas.com was not compensated for this release but previously was compensated by third party on behalf of SBFM: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894